This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
STERIS (STE) Q4 Earnings Surpass Estimates, Gross Margin Rises
by Zacks Equity Research
Robust performances across all four reporting segments drive STERIS' (STE) fiscal fourth-quarter revenues.
Globus Medical (GMED) Q1 Earnings Miss Estimates, Margins Dip
by Zacks Equity Research
According to Globus Medical (GMED), its Q1 results reflect modest revenue growth against a difficult prior-year comparison, coupled with COVID-related revenue impacts in key countries.
Haemonetics (HAE) Q4 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Robust performance by Plasma and Hospital businesses drove Haemonetics' (HAE) revenues in the fiscal fourth quarter.
Here's Why You Should Hold on to Henry Schein (HSIC) Now
by Zacks Equity Research
Investors are optimistic about Henry Schein (HSIC) on favorable international Dental business trends and bullish guidance.
Here's Why You Should Hold on to CVS Health (CVS) For Now
by Zacks Equity Research
Investors are optimistic about CVS Health's (CVS) better-than-expected results and strong retail sales.
National Vision (EYE) Tops Q1 Earnings Estimates, Cuts '22 View
by Zacks Equity Research
National Vision (EYE) reports better-than-expected earnings and an increase in store count for the first quarter.
SmileDirectClub (SDC) Q1 Earnings Lag Estimates, Margins Fall
by Zacks Equity Research
SmileDirectClub's (SDC) revenues declined year over year in the first quarter due to a drop in unique aligner shipments.
Charles River (CRL) DSA Arm Prospers, Currency Headwind Stays
by Zacks Equity Research
Charles River (CRL) broadens the scope of the products and services across the drug discovery and early-stage development continuum through focused acquisitions.
Zimmer Biomet's (ZBH) Procedure Volume Grows, Costs Rise
by Zacks Equity Research
Zimmer Biomet's (ZBH) recently completed the spin-off of the non-core dental and spine business is expected to prove strategic.
Insulet (PODD) Q1 Earnings Surpass Estimates, Margins Grow
by Zacks Equity Research
Robust adoption of Omnipod DASH and record new customer starts have contributed to Insulet's (PODD) Q1 performance.
Medtronic (MDT) Global Business Gains Ground, Volume Woes Stay
by Zacks Equity Research
Since the start of fiscal 2022, Medtronic (MDT) has been witnessing a strong recovery and displayed a return to growth.
Myriad Genetics (MYGN) Reports Loss in Q1, Gross Margin Down
by Zacks Equity Research
Myriad Genetics' (MYGN) sales in the majority of the operating segments improved in the first quarter despite a challenging business environment.
Illumina (ILMN) Q1 Earnings Beat Estimates, Gross Margin Down
by Zacks Equity Research
Illumina (ILMN) ended the first quarter with better-than-expected earnings and revenues on strength in Core Illumina and the GRAIL businesses driving the top line.
Phibro (PAHC) Q3 Earnings Lag Estimates, 2022 Revenue View Up
by Zacks Equity Research
In Q3, Phirbo (PAHC) reports growth in the Animal Health business on higher sales of processing aids, which are used to improve production efficiency in the ethanol fermentation industry.
Thermo Fisher (TMO) End Markets Strong, Margin Under Pressure
by Zacks Equity Research
Thermo Fisher's (TMO) core business strength was broad-based across segments, end markets, and geographies.
Bruker (BRKR) Q1 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Revenue growth across the BSI and BEST businesses drove Bruker's (BRKR) first-quarter 2022 revenues.
Tandem Diabetes (TNDM) Q1 Earnings Lag Estimates, Sales View Up
by Zacks Equity Research
Robust pump shipments and growth in the installed customer base are driving Tandem Diabetes' (TNDM) first-quarter top line.
Cardiovascular Systems' (CSII) Q3 Earnings Top Estimates
by Zacks Equity Research
Cardiovascular Systems' (CSII) third-quarter revenues declined year over year due to lower Coronary and peripheral revenues.
NuVasive (NUVA) Q1 Earnings Beat Estimates, 2022 View Up
by Zacks Equity Research
Robust sales performance across all U.S. product lines drove NuVasive's (NUVA) Q1 top line.
Charles River (CRL) Q1 Earnings Top, Gross Margin Falls
by Zacks Equity Research
Charles River (CRL) Q1 results highlight 9.8% organic revenue growth, driven by strength across all three segments.
CVS Health (CVS) Q1 Earnings Top Estimates, '22 EPS View Up
by Zacks Equity Research
CVS Health (CVS) reports better-than-expected results for Q1, with robust segmental performance driving the top line.
IDEXX (IDXX) Q1 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Strong sales at the CAG and Water businesses drove IDEXX's (IDXX) first-quarter 2022 revenues.
Here's Why You Should Hold on to Edwards Lifesciences (EW) Now
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences (EW) given the strong demand for its RESILIA tissue valves and the PASCAL system.
Henry Schein (HSIC) Q1 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Robust performances by all three operating segments drove Henry Schein's (HSIC) first-quarter 2022 revenues.
Omnicell (OMCL) Q1 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Robust sales performance across Omnicell's (OMCL) operating segments has contributed to the first-quarter top line.